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Comparability of the Australian National Cancer Symptom Trials (CST)
Group's Study Populations to National Referrals to Non-CST Specialist
Palliative Care Services Participating in the Palliative Care Outcomes
Collaboration
Abstract

Using the results of Phase III studies in clinical practice depends on how representative study participants are
of the clinical population to whom the results will be applied. The closer the characteristics between the
subgroup who participate in a clinical trial and the whole population, the easier it is for clinicians to apply the
results directly to the patient that he/she is treating. Trial participation is generally more happenstance than a
systematic sampling of a population and is limited by eligibility criteria that do not reflect the entire clinical
population. Phase III study populations tend to be younger with fewer comorbidities and not represent the
gender and ethnicity of the target population, limiting generalizability of results. When moving from Phase III
studies to Phase IV postmarketing studies, there will be differences in the populations prescribed the
medications and the outcomes achieved, highlighting the gap between gold-standard evidence from Phase III
randomized studies and the application of that evidence in real-world practice. Palliative care services are
referral based, yet there are no standard national or international referral criteria. As such, the populations
served by specialist palliative care services are ill defined, complicating the problem of defining a
"representative" population even further. Key characteristics have been suggested to aid generalizability of
research findings in palliative care, although these are poorly reported. In palliative care, large-scale Phase III,
symptom control effectiveness studies are being conducted successfully. This includes the work of the
Australian National Cancer Symptom Trials (CST) group. Can the findings from these studies be generalized
to the broader palliative cancer care population in the same health system? The aim of this analysis was to
compare key demographic factors between participants with cancer in these Phase III studies and people
referred to nontrial specialist palliative care services using standard prospective data collection. The null
hypothesis was that there was no difference between participants' characteristics.
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to assess the accuracy of SCORTEN in predicting inhospital mortality. These studies overall have shown
that the SCORTEN performance during the first
five days of hospitalization was excellent and is best
on Day 3.4 The most recent accuracy study was a retrospective study that included adult and pediatric
patients admitted to a burn center with biopsyconfirmed SJS/TEN. SCORTEN scores were calculated on Day 1 and Day 3 of hospital admission, and
they compared predicted with actual mortality in these
patients. This study, however, claims that the accuracy
of the SCORETEN model remains unclear and could
be more precise, therefore encouraging future studies
to explore other variables and a possible reformulated
SCORTEN.5 These studies exemplify that like many
things in medicine, mortality probability models
cannot 100% predict outcomes in individual patients.
That said, the presence of palliative medicine is
increasing in ICU settings, and there is an increasing
need for prognostic tools and evidence-based practice
to help facilitate GOC discussion. In support of the
traditional palliative care philosophy, recent findings
show that aggressive end-of-life care does not correlate
with improved perception of the medical care
received near time of death and that many patients
near the end of life often prefer palliative treatments
over aggressive life-extending therapies.6 Because the
SCORTEN assessment was available and done quickly,
we were able to present this patient’s family members
with an accurate prognostication of their loved one’s
in-hospital mortality. With these data, we were able
to have a more direct GOC discussion, and the patient
was able to die with care in accordance with her
wishes.
This case study and discussion demonstrates the
acuity of decision making necessary in a patient with
severe integument injury with a >90% in-hospital
mortality likelihood. It additionally provides palliative
care providers with the knowledge of the SCORTEN
illness severity and in-hospital mortality scale, demonstrating how having such a tool can aid in expediting
GOC discussions, leading to improved patient end-oflife care.
Olivia M. Seecof, MD
Department of Family and Community
Medicine
Thomas Jefferson University
Philadelphia, Pennsylvania, USA
E-mail: Olivia.seecof@jefferson.edu
John Liantonio, MD
Division of Geriatrics and Palliative Care
Department of Family and Community
Medicine
Thomas Jefferson University
Philadelphia, Pennsylvania, USA
https://doi.org/10.1016/j.jpainsymman.2018.09.019
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Comparability of the Australian
National Cancer Symptom Trials
(CST) Group’s Study Populations to
National Referrals to Non-CST
Specialist Palliative Care Services
Participating in the Palliative Care
Outcomes Collaboration
Introduction
Using the results of Phase III studies in clinical practice depends on how representative study participants
are of the clinical population to whom the results will
be applied. The closer the characteristics between the
subgroup who participate in a clinical trial and the
whole population, the easier it is for clinicians to apply
the results directly to the patient that he/she is treating. Trial participation is generally more happenstance than a systematic sampling of a population
and is limited by eligibility criteria that do not reflect
the entire clinical population.1
Phase III study populations tend to be younger with
fewer comorbidities and not represent the gender and
ethnicity of the target population, limiting generalizability of results.1,2 When moving from Phase III
studies to Phase IV postmarketing studies, there will
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be differences in the populations prescribed the medications and the outcomes achieved,3 highlighting the
gap between gold-standard evidence from Phase III
randomized studies and the application of that evidence in real-world practice. Palliative care services
are referral based, yet there are no standard national
or international referral criteria. As such, the populations served by specialist palliative care services are ill
defined, complicating the problem of defining a
‘‘representative’’ population even further. Key characteristics have been suggested to aid generalizability
of research findings in palliative care,4 although these
are poorly reported.
In palliative care, large-scale Phase III, symptom
control effectiveness studies are being conducted successfully. This includes the work of the Australian National Cancer Symptom Trials (CST) group.5e10 Can
the findings from these studies be generalized to the
broader palliative cancer care population in the same
health system?
The aim of this analysis was to compare key demographic factors between participants with cancer in
these Phase III studies and people referred to nontrial
specialist palliative care services using standard prospective data collection. The null hypothesis was that there
was no difference between participants’ characteristics.

Methods and Analysis
This is a comparison of two independent but complementary consecutive cohorts generated contemporaneously through clinical trials and clinical quality
initiatives nationally in Australia. This study compared
age, sex, cancer diagnosis, language, socioeconomic
status (using the Index of Relative Advantage and
Disadvantage11), and Australian-modified Karnofsky
Performance Status12 in people with cancer enrolled
in CST Phase III clinical studies5e10 in people with
cancer registered by the Australian National Palliative
Care Outcomes Collaboration (PCOC) during the
period 2013e2016 from sites not participating in CST.

Statistical Considerations
Demographic data were summarized using counts,
percentages, medians, and interquartile ranges.
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Median ages and functional status were compared using the Wilcoxon rank sum test, whereas differences
between the distribution of gender, language, and socioeconomic status were compared using Pearson’s
chi-squared test. Analyses were performed using R
(Version 3.4.0, 2017; Auckland, New Zealand). No
missing data were imputed. This study is reported using the STROBE framework for observational
studies.13
Anonymized, deidentified data in secondary analysis
required no further ethical review. Primary data collection was covered by relevant Human Research Ethics
Committees.

Results
Nine hundred two people with cancer participated
in six Phase III placebo-controlled, randomized
controlled trials across 17 sites (Table 1). A consecutive cohort of 75,240 patients with a cancer diagnosis
seen in 117 non-CST sites were the comparator
population.
The CST cohort were younger (median age 71 [interquartile range {IQR} 62e79]) than the PCOC population (median 73 [IQR 63e81]; P ¼ 0.003). There was
no difference in sex between the groups (56.1% male
in CST; 54.8% PCOC; P ¼ 0.483), but the CST cohort
had a higher proportion of English speakers (CST
95.0%; PCOC 92.2%; P ¼ 0.004). The most frequent
four diagnoses in the CST cohort were as follows: lung,
colorectal, gynecological, and prostate cancers. For
PCOC, this was as follows: lung, colorectal, other gastrointestinal tract, and breast cancers (Table 2). Functional status, unlike the parameters reported in
Table 3, changes over time in life-limiting illnesses so
the decision was made to report the first Australianmodified Karnofsky Performance Status in each database for each person. The studies on delirium and inoperable malignant bowel obstruction tended to be later
in people’s clinical course, while studies on breathlessness tended to be in people with better levels of function (Table 3). Overall, people in CST studies tended
to have a better level of function with a median score
of 60 (IQR 50e70) than people referred to PCOC (median 50 [IQR 30e60]; P < 0.001).

Table 1
Double-Blind, Parallel-Arm, Multisite, Placebo-Controlled, Phase III Studies for Symptom Control in People With
Advanced Cancer
Study Drug
Sertraline
Extended-release morphine
Megestrol or dexamethasone
Ketamine
Octreotide
Risperidone or haloperidol
Total

People With Cancer Randomized

Total Randomized

Percentage of Cancer

75
122
190
185
112
218
902

223
284
190
185
112
247
1241

33.6
43.0
100
100
100
88.3
72.7
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Table 2
Comparison of the Fixed Characteristics of Participants in National, Multisite Phase Ⅲ Controlled Clinical Studies for
Symptom Control (Cancer Symptom Trials [CST] Group) With the Specialist Palliative Care Population in
Nonparticipating Sites that were Part of the Palliative Care Outcomes Collaboration (PCOC)
Population
PCOC (n ¼ 75,240)

Population Characteristics
a

Age (median; IQR)
Sex, n (%)b
Men
Women
Languagec
English
Non-English
Socioeconomic status, n (%)d
Index of Relative Socio-economic Advantage and Disadvantage (quintile)
1
2
3
4
5

CST (n ¼ 902)

73.0 (63e81)

71.0 (62e79)

41,257 (54.8)
33,967 (45.2)

498 (56.1)
390 (43.9)

68,115 (92.2)
5782 (7.8)

774 (95.0)
41 (5.0)

13,241
10,877
14,106
15,366
21,326

149
136
136
212
246

(17.7)
(14.5)
(18.8)
(20.5)
(28.5)

(17.0)
(15.5)
(15.5)
(24.1)
(28.0)

Population
PCOC (n ¼ 75,240)
Population Characteristics
Diagnosis
Lung
Colorectal
Other GIT
Breast
Pancreatic
Prostate
Hematological
Head and neck
Gynecological
Other urological
Other primary
Skin
Unknown primary
CNS
Bone and soft tissue
Malignantdother

16,425
8540
7140
5535
5044
4994
4938
4006
3578
3275
2997
2971
2077
1611
1171
974

(21.8)
(11.4)
(9.4)
(7.4)
(6.7)
(6.6)
(6.6)
(5.3)
(4.8)
(4.4)
(4.0)
(3.9)
(2.8)
(2.1)
(1.6)
(1.3)

CST (n ¼ 902)

Med. Age

% Male

72
73
72
67
73
79
76
68
70
76
72
72
77
65
71
74

59.4
54.9
62.1
51.8
56.1
67.8
67.7

Med. Age
261
125
57
55
35
82
27
13
85
34
6
40
6
4
10
62

(28.9)
(13.9)
(6.3)
(6.1)
(3.9)
(9.1)
(3.0)
(1.4)
(9.4)
(3.8)
(0.6)
(4.4)
(0.7)
(0.4)
(1.1)
(6.9)

72
71
68
67
68
77
74
e

% Male
61.7
48.0
68.4
54.3
74.1

e

75

74.4

71

77.5

e
e
e
e
e

IQR ¼ interquartile range; GIT ¼ gastrointestinal tumor; CNS ¼ central nervous system.
a
Age difference between groups: P ¼ 0.003.
b
16 (0.02%) missing PCOC; 14 (1.6%) missing CST: P ¼ 0.483 for between-group comparison.
c
1343 (1.8%) missing PCOC; 87 (9.6%) missing CST; P ¼ 0.004 for between-group comparison.
d
324 (0.4%) missing PCOC; 23 (2.5%) missing CST; P ¼ 0.022 for between-group comparisons.
e
Cell count <25 so not calculated.

Service delivery models were similar between the cohorts (Table 4).
Patients referred to PCOC are more likely to have a
higher socioeconomic status than the general Australian population. The highest two Index of Relative
Advantage and Disadvantage quintiles are overrepresented in both cohorts, with this being even greater
in CST (52.1%; PCOC 49.0%; P ¼ 0.022).

Discussion
This study found demographic differences between
a Phase III study cohort and the general palliative care
population consistent with differences described in
other clinical specialties. Despite these statistical differences, the findings of these Phase III studies are

likely to be able to be applied to the broader palliative
care population.
Differences in cancer diagnoses almost certainly
reflect the symptoms explored: breathlessness and
anorexia are both prevalent in lung cancer 5,6; bowel
obstruction is prevalent in gynecological cancers9;
and pain is frequently encountered in late-stage metastatic breast and prostate cancers.8
In efficacy studies that have the most stringent eligibility criteria, the population is likely to be healthier
with fewer comorbidities, often reflecting only the index clinical presentation. By contrast, effectiveness
studies have broader eligibility criteria, more closely
reflecting day-to-day practice. This study demonstrates
that for the criteria compared, CST studies are effectiveness studies maximizing their generalizability.
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Table 3
Comparison of Variable Factors (Functional Status) of
People Participating in Cancer Symptom Trials (CST)
Studies Group With the Population in Non-CST Sites that
were Participating in the Australian National Palliative
Care Outcomes Collaboration (PCOC)
PCOC (%)

CST (%)

AKPS

N ¼ 75,240

N ¼ 902

Median (IQR)

50 (30e60)

60 (50e70)

2.4
10.6
9.6
15.3
22.7
21.2
10.9
3.8
1.2
0.1
2.3

0.0
4.4
5.4
14.2
23.4
26.1
19.2
5.4
0.8
0.0
1.1

10
20
30
40
50
60
70
80
90
100
Missing

AKPS ¼ Australian-modified Karnofsky Performance Status; IQR ¼ interquartile range.
P < 0.001 (Wilcoxon rank sum test).

In palliative care, a framework for classifying
research subpopulations to which the research findings are being applied by clinicians, health planners,
and funders in real-world settings has been suggested.14 Existing literature often inadequately describes the characteristics of patients, limiting the
utility of results. Hjermstad et al. identified wide variation in palliative care services and patients.15 Patients’
characteristics differed when compared across predefined categories of participating centers.
Detailed characterization is the first step in
improving use of palliative care research. Palliative
care cancer populations are inconsistently and insufficiently described when reporting randomized
controlled trials requiring investigators to improve
this aspect of trial reporting.16e18

Table 4
Comparison of the Sites’ Characteristics in National,
Multisite Phase Ⅲ Controlled Clinical Studies for
Symptom Control (Cancer Symptom Trials [CST] With
the Specialist Palliative Care Population in Non-CST Sites
that were Participating in the Palliative Care Outcomes
Collaboration [PCOC])

Item
Inpatients/consults
Community only
Consult only
Inpatients and community
Community and consult
Inpatients and community
and consult

PCOC
(n ¼ 75,240)
117 Sites
55
34
4
16
5
3

(47%)
(29%)
(3%)
(14%)
(4%)
(3%)

CST
(n ¼ 902)
17 Sites
9
1
3
2
0
2

(53%)
(6%)
(18%)
(12%)
(0%)
(12%)
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Limitations
The data from the PCOC cohort do not contain comorbidity data, and the research database has comorbidities only relevant to each individual study. Stage of
disease was also not available. Future work in this area
should collect such data prospectively.

Strengths
All data in this data set were generated prospectively
with high levels of completeness. The use of the data
in this secondary analysis is directly in keeping with
the purposes for which the data were collected.

Clinical Implications
The CST has run effectiveness studies with the widest possible eligibility criteria to ensure that the generalizability of the findings is maximized. The findings
in this study are that the CST cohort largely mirrors
the palliative care population that we serve. This gives
confidence for clinicians to explore applying the
findings from these studies to their own setting, as
many have done given demonstrated changes in
practice.19,20

Research Implications
Continuing to refine the evidence base for therapeutic interventions in palliative care is paramount if
we are to realize the vision to personalize care. Palliative care Phase II and III studies need to be effectiveness studies built on the broadest possible population
of palliative care patients.
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When We Document End-of-Life
Care, Words Still Matter
To the Editor:
In the September 2018 edition of the Journal of Pain
and Symptom Management, the study ‘‘Language used by
health care professionals to describe dying at an acute
care hospital’’ focused on specific word choices when
documenting end-of-life care.1 They accurately note
that, in acute care settings, the patient’s medical record often becomes the primary mechanism for
communication between providers. Imprecise documentation can lead to poor transfer of knowledge
and even implicit bias.2 Wentlandt et al. describe the
‘‘implied state’’ category as most frequently used by
nonpalliative care providers, which labels patients by
the care they receive (e.g., ‘‘he receives comfort care’’)
without clearly indicating estimated prognosis. Specific terms such as ‘‘dying,’’ ‘‘die,’’ and ‘‘passing’’ (a
word that many would characterize as an inexact
euphemism) were only documented 24.7% of the
time.
Words still matter. Provider discomfort compassionately employing clear, direct terms (e.g., ‘‘your father
is dying’’) has been well described.3,4 The unintended
consequences of using oblique terminology (e.g.,
‘‘your father is transitioning’’) certainly include
miscommunication (‘‘you mean my father has been
moved to a different room?’’) and missed or delayed
opportunities to engage in the grieving process. What
this study underlines is the remarkable extent to
which provider discomfort talking about death and
dying extends away from the patient/family encounter
to the clinical chart: we are anxious to say these things
even to each other.
We applaud the efforts of Dr. Wentlandt and colleagues to shine the light onto our communication
practices within the medical record. Perhaps, these
findings offer the opportunity for our own hospice
and palliative care field to clearly define best communication practices. For example, the Journal of the American Geriatrics Society recently took a stance on language
by requiring its authors to use the term ‘‘older adult’’
when referring to someone aged 65 years or older
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rather than seniors or elderly.5 We suggest JPSM, and
other discipline-specific journals consider adopting
similar word choice policies related to terminology
of death and dyingdlet’s set a standard for others to
follow.
Sincerely,
Anne Kelemen, LICSW
Section of Palliative Care
MedStar Washington Hospital Center
Washington
District of Columbia
USA
Hunter Groninger, MD, FAAHPM
Department of Medicine
Georgetown University Medical Center
Washington
District of Columbia
USA
E-mail: hunter.groninger@medstar.net
https://doi.org/10.1016/j.jpainsymman.2018.09.015
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Response to Hyoscine Butylbromide
for the Management of Death Rattle:
Sooner Rather Than Later
Dear Editor:
I read the recent paper regarding death rattle treatment with great interest.1 The authors are commended for giving consideration to this naturally
occurring patient noise that is distressing to clinicians
and families.
Clinicians have largely believed there is no patient
distress as death rattle develops in the context of
declining consciousness. We established that there is
no patient distress associated with the development

